CommercialCoverageMedium impact
08.00.91f, Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)
Independence Blue Cross·Pulmonology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Medical necessity criteria for Alpha-1 Antitrypsin Therapy medications (Prolastin-C, Aralast NP, Glassia, Zemaira) have been updated for commercial plans. This affects coverage determinations and prior authorization requirements for these specialized respiratory medications.
Action Required
By July 1, 2025: Billing team must review updated medical necessity criteria for Alpha-1 Antitrypsin Therapy medications. Update prior authorization documentation requirements and ensure providers are aware of new coverage criteria. Verify billing procedures align with new medical necessity standards to prevent claim denials.